The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (13 analysts) rates it buy, with a mean price target of $40.
Commerzbank AG
CBK.DE · GER · EUR · Market cap $40.7B
Commerzbank AG provides banking and capital market products and services to private and small business customers, corporate, financial service providers, and institutional clients in Germany, rest of Europe, the Americas…
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price39.89 EUR at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: 44.15 EUR to 73.59 EUR, base estimate 45.00 EUR (screen dated 2026-11-13).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Commerzbank AG holds its Distribution at $39.89. The statistical read favours the sellers, held for 19 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 19 days |
| Price at the screen | $39.89 |
| Valuation | 14.44 trailing · 9.61 forward price to earnings |
| Values screen | FAIL |
| Beta | 0.70 |
Five Screens, Shown in Full
Does not pass. Business activity: conventional financial services (interest-based)
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Its core business involves an activity the values screen does not clear. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Commerzbank does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CBK.DE's ethical verdict changes
Today CBK.DE does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly an 11% discount to our 45.00 EUR fair value, strong competitive moat, 10.10% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in EUR, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 11.4% discount to the base estimate.
Third-party analyst targets: 12 covering, consensus Buy. The average target sits +5% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate 45.00 EUR, with a range of 44.15 EUR to 73.59 EUR, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it stands out
A 10%-growth business trading at just 9.6x forward earnings, with a strong competitive moat. That is an 11% discount to our 45.00 EUR fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 12 analysts rate it Buy with a 42.00 EUR average target, about 5% above the screened price.
| Forward P/E | 9.6xfairly priced for its growth rate |
| Trailing P/E | 14.4xreasonably valued |
| EPS, trailing | 2.61 |
| EPS, forward | 3.92 |
| Revenue growth | +10.1%steady growth |
| Profit margin | 26.4%healthy profit margins |
| Return on equity | 9.7%a modest return on shareholder capital |
| Dividend yield | 2.99% |
| Beta | 0.70steadier than the market |
| 52-week range | 29.01 - 43.37 |
| Moat | STRONG |
| Market cap | $40.7B |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Germany and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCBK.DE trades on GER (the company is based in Germany). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 10.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (13 analysts) rates it buy, with a mean price target of $40.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (13 analysts) rates it buy, with a mean price target of $40.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (13 analysts) rates it buy, with a mean price target of $40.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (13 analysts) rates it buy, with a mean price target of $40.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (13 analysts) rates it buy, with a mean price target of $40.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (13 analysts) rates it buy, with a mean price target of $40.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Commerzbank Says Treasuries Rally as US Equity Futures Decline, Oil Prices Slip, US Dollar Lower Yahoo Finance · 13 Oct 2026
- Stocks Rise as Oil Eases After Russian Diesel Deal Despite Middle East Tension Yahoo Finance · 12 Oct 2026
- Commerzbank Says Treasuries Are Supported as Oil Prices Drop After Trump Rules Out Iran Attacks Before Midterms Yahoo Finance · 9 Oct 2026
- Is Commerzbank (XTRA:CBK) Fairly Valued After The HVB Deal Talk? Yahoo Finance · 8 Oct 2026
- Treasuries Advance After Strong 10-Year Auction as Brent Tops $102, Commerzbank Says Yahoo Finance · 8 Oct 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $34.90 | +3.8% | $1.10 | $1,069 | +6.9% |
| 2 months | $33.54 | +8.0% | $1.10 | $1,113 | +11.3% |
| 3 months | $30.59 | +18.4% | $1.10 | $1,220 | +22.0% |
| 6 months | $34.21 | +5.9% | $1.10 | $1,091 | +9.1% |
| 1 year | $26.99 | +34.2% | $1.10 | $1,383 | +38.3% |
| 2 years | $14.51 | +149.6% | $1.75 | $2,616 | +161.6% |
| 3 years | $9.06 | +299.8% | $2.10 | $4,230 | +323.0% |
| 5 years | $5.88 | +515.6% | $2.30 | $6,546 | +554.6% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CBK.DE does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.